Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Clovis Oncology: Chardan reiterates Sell — [+] SOLO-2 data (AZN) highlights competitive risks in PARPi (66.95)Chardan notes positive Lynparza (<strong>AZN</strong>) results in ovarian cancer maintenance raise competitive risks for Rubraca. While they understand that success for a second PARPi in the setting of ovarian cancer maintenance therapy arguably further de-risks PARPi as a class in the indication, this de-risking needs to be balanced by the competitive pressures generated by multiple effective PARPis in the ovarian cancer space. In addition, positive results for competitors in the second-line maintenance setting puts pressure on Rubraca's approved indication of third line or later therapy since significant market penetration by niraparib (<strong>TSRO</strong>) and/or Lynparza in second-line maintenance therapy could restrict the market for Rubraca in the third line through PARPi cross-resistance. Finally, the positive SOLO-2 result raises the possible risk that ARIEL3 could fail in an absolute sense (e.g. trial failure) or in a relative sense (e.g. trial success with efficacy inferior to niraparib and/or Lynparza). Competitor androgen receptor (AR) inhibitor combinations will likely limit Rubraca utility in prostate cancer; $36 tgt.</td> </tr></table>"